Guardant Health Revenue 2017-2022 | GH
Guardant Health revenue from 2017 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Guardant Health Annual Revenue
(Millions of US $) |
| 2022 |
$450 |
| 2021 |
$374 |
| 2020 |
$287 |
| 2019 |
$214 |
| 2018 |
$91 |
| 2017 |
$50 |
| 2016 |
$25 |
Guardant Health Quarterly Revenue
(Millions of US $) |
| 2022-12-31 |
$127 |
| 2022-09-30 |
$117 |
| 2022-06-30 |
$109 |
| 2022-03-31 |
$96 |
| 2021-12-31 |
$108 |
| 2021-09-30 |
$95 |
| 2021-06-30 |
$92 |
| 2021-03-31 |
$79 |
| 2020-12-31 |
$78 |
| 2020-09-30 |
$75 |
| 2020-06-30 |
$66 |
| 2020-03-31 |
$68 |
| 2019-12-31 |
$63 |
| 2019-09-30 |
$61 |
| 2019-06-30 |
$54 |
| 2019-03-31 |
$37 |
| 2018-12-31 |
$33 |
| 2018-09-30 |
$22 |
| 2018-06-30 |
$19 |
| 2018-03-31 |
$17 |
| 2017-12-31 |
|
| 2017-09-30 |
$11 |
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.359B |
$0.450B |
|
Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
|
